肿瘤细胞治疗研究
英文原题：Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.
在过去十年中，抗CD19 CAR-T细胞疗法引领了B细胞非霍奇金淋巴瘤治疗模式的转变，最初获批用于复发/难治性（R/R）大B细胞淋巴瘤，随后获批用于R/R套细胞淋巴瘤和滤泡性淋巴瘤。
在过去十年中，抗CD19 CAR-T细胞疗法引领了B细胞非霍奇金淋巴瘤治疗模式的转变，最初获批用于复发/难治性（R/R）大B细胞淋巴瘤，随后获批用于R/R套细胞淋巴瘤和滤泡性淋巴瘤。在淋巴瘤领域，人们不断努力扩展治疗适应场景。多项报告支持CAR-T细胞在有中枢神经系统疾病受累患者中的安全性和有效性。用于治疗霍奇金淋巴瘤的抗CD30 CAR-T细胞正在开发中，旨在寻找T细胞恶性肿瘤最佳靶点的早期研究也在进行中。抗CD19/CD20和CD19/CD22双靶向CAR-T细胞正在研究中，以期提高抗淋巴瘤活性并克服肿瘤免疫逃逸。异体CAR产品工程正在进行中，代表了一种可快速获得的“现货型”且可能更适用的产品。在本手稿中，我们将聚焦于CAR-T细胞疗法治疗淋巴瘤的最新进展，包括该领域的新适应场景和未来展望，并回顾截至2023年10月过去十年间文献报道的数据。
In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell lymphomas and subsequently for R/R mantle cell and follicular lymphoma. Many efforts are continuously being made to extend the therapeutic setting in the lymphoma field. Several reports are supporting the safety and efficacy of CAR-T cells in patients with central nervous system disease involvement. Anti-CD30 CAR-T cells for the treatment of Hodgkin lymphoma are in development and early studies looking for the optimal target for T-cell malignancies are ongoing. Anti-CD19/CD20 and CD19/CD22 dual targeting CAR-T cells are under investigation in order to increase anti-lymphoma activity and overcome tumor immune escape. Allogeneic CAR product engineering is on the way, representing a rapidly accessible 'off-the-shelf' and potentially more fit product. In the present manuscript, we will focus on recent advances in CAR-T cell therapy for lymphomas, including new settings and future perspectives in the field, reviewing data reported in literature in the last decade up to October 2023.
MEMBER ACCOUNT
登录成功会直接打开下一页。
